Mahdi Rezai

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

Gϋnter von Minckwitz, Andreas Schneeweiß, Sibylle Loibl et al. · The Lancet Oncology · 2014 · 1K citations

Gbg 66, Breast Oncology, Medicine +7

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study

S. Loibl, Michael Untch, Nicole Burchardi et al. · Annals of Oncology · 2019 · 666 citations

Clinical Results, Breast Oncology, Biomarker Analysis +7

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study

Michael Untch, Mahdi Rezai, Sibylle Loibl et al. · Journal of Clinical Oncology · 2010 · 550 citations · Full text

Surgical Oncology, Oncology, High Pcr Rate +13

Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer

Gϋnter von Minckwitz, Holger Eidtmann, Mahdi Rezai et al. · New England Journal of Medicine · 2012 · 528 citations